(NASDAQ: GTBP) Gt Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.81%.
Gt Biopharma's earnings in 2025 is -$11,672,000.On average, 1 Wall Street analyst forecast GTBP's earnings for 2025 to be -$6,155,625, with the lowest GTBP earnings forecast at -$6,155,625, and the highest GTBP earnings forecast at -$6,155,625. On average, 1 Wall Street analyst forecast GTBP's earnings for 2026 to be -$2,638,125, with the lowest GTBP earnings forecast at -$2,638,125, and the highest GTBP earnings forecast at -$2,638,125.
In 2027, GTBP is forecast to generate -$2,224,301 in earnings, with the lowest earnings forecast at -$2,224,301 and the highest earnings forecast at -$2,224,301.